Amsterdam, Munich, Boston, November 22, 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announces the FDA approval of SoliquaTM 100/33 for the treatment of adults with type 2 diabetes. SoliquaTM 100/33 is the fixed-ratio combination of Lantus® (a Sanofi drug) and Lixisenatide, developed by the Danish LSP portfolio company Zealand Pharma, and will be marketed by Sanofi.
SoliquaTM 100/33 will be delivered in a single pre-filled pen for once-daily dosing and will be available in U.S. retail pharmacies in January 2017. A formal decision by the European Commission is expected in the coming months.
Zealand Pharma will receive an $ 25 mln milestone payment as well as double-digit royalties. Analysts’ consensus estimate shows peak sales above $ 2 bln.
Commenting on the approval, René Kuijten, Managing Partner at LSP, says: ‘’We invested at an early stage in Zealand Pharma, based on the unique peptide discovery platform of the company, and have actively contributed to its growth. Our hypothesis that Zealand’s drug could help diabetes patients has now been confirmed by the FDA. We congratulate Sanofi and Zealand Pharma with this remarkable success. The positive impact that LSP has on patients’ lives has again been evidenced in one of the largest disease indications”.
The press release of Sanofi can be found here.
The press release of Zealand Pharma can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.